Add to my selection

BESREMI (ropeginterféron alfa-2b)

Medicine - Posted on Aug 07 2025

Active substance (DCI)

ropeginterféron alfa-2b

history (2)

7/9/25

BESREMI (ropeginterferon alfa-2b) - Polycythaemia vera

Summary of opinion Favourable opinion for reimbursement only in the indication “as monotherapy in adults for the treatment o...

CAV :
54321

icône flèche
12/16/20

BESREMI (ropeginterferon alfa-2b)

Key points Unfavourable opinion for reimbursement as monotherapy in adults for the treatment of polycythaemia vera without s...

CAV :
54321

icône flèche

Technical information

ATC code

L03AB15

Manufacturer

AOP ORPHAN PHARMACEUTICALS FRANCE

Presentation

BESREMI 250 microgrammes/0,5 mL, solution injectable en stylo prérempli
1 cartouche(s) en verre de 0,5 ml dans un stylo pré-rempli avec 2 aiguilles (CIP : 34009 301 994 1 1)

All our publications

Bone marrow diseases

Congenital, genetic and rare diseases

Drug therapy

Hematologic cancers

My account

You do not have a saved search

BESREMI (ropeginterféron alfa-2b)

BESREMI (ropeginterferon alfa-2b) - Polycythaemia vera

BESREMI (ropeginterferon alfa-2b)

Follow us :